Interactive Strength Inc. (Nasdaq:TRNR) Regains Full Compliance With Nasdaq Continued Listing Standards
AUSTIN, TX / ACCESSWIRE / December 10, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative...
AUSTIN, TX / ACCESSWIRE / December 10, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or "the Company"), maker of innovative...
VICTORIA, BC / ACCESSWIRE / December 10, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that...
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide...
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0)...
Leading Contract Research Organization integrates H1’s Trial Landscape platform to optimize global site selection, enhance diversity efforts, and streamline operational...
HUNTINGTON BEACH, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ACC Medlink, a leading provider of long-distance medical transportation services, proudly...
WINTER PARK, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition is thrilled to announce the opening of its inaugural...
RED has been designed to duplicate test performance of traditional balloon expulsion test (BET) and manual sensation testing devices without...
Data from Phase 1b/2 clinical trial to be presented at 2024 San Antonio Breast Cancer Symposium (SABCS) show encouraging clinical...
Fischer Imaging Delivers MammoCAT to Johns Hopkins University for Preclinical TestingATLANTA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Mammograms are one...
New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT...
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation...
- Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee...
– Marks first time as a public company that Conavi is presenting at an investor event – – Live webcast...
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of...
WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been...
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal...
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY...
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of...